Relevant bibliographies by topics / Hyperlipoproteinaemia

Contents

  1. Journal articles
  2. Books
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Hyperlipoproteinaemia'

Author: Grafiati
Published: 4 June 2021
Last updated: 31 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hyperlipoproteinaemia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hyperlipoproteinaemia"

1

Sniderman, Allan D., Jean-Charles Hogue, Jean Bergeron, Claude Gagné, and Patrick Couture. "Non-HDL cholesterol and apoB in dyslipidaemia." Clinical Science 114, no. 2 (December 11, 2007): 149–55. http://dx.doi.org/10.1042/cs20070265.

Full text
Abstract:
On the basis of a high correlation, non-HDL-C (non-high-density lipoprotein cholesterol) and apoB (apolipoprotein B) have been suggested to be of equivalent value for clinical practice; however, the strength of this relationship has not been examined in detail in patients with dyslipidaemia. The present study examines the variance of non-HDL-C compared with apoB in 1771 consecutive patients evaluated in a lipid clinic. These patients were divided into normolipidaemic subjects (n=407), type I hyperlipoproteinaemia (n=16), type IIa (n=736) and IIb (n=231) hyperlipoproteinaemia, type III hyperlipoproteinaemia (n=38), type IV hyperlipoproteinaemia (n=509) and type V hyperlipoproteinaemia (n=101). The relationship between non-HDL-C and apoB was examined both in terms of correlation and concordance. Correlation was high, but concordance was only moderate in the normolipidaemic subjects and in those with type IIa and type IIb hyperlipoproteinaemia. Correlation and concordance were both low in the subgroups with type III and type V hyperlipoproteinaemia. In those with type IV hyper-lipoproteinaemia, correlation was moderately high (r=0.74), but concordance was only fair. In conclusion, our results indicate that there is substantial variance of apoB for given values of non-HDL-C in many dyslipidaemic subjects. It follows that correlation is not adequate as a sole judge of equivalence of laboratory parameters.
APA, Harvard, Vancouver, ISO, and other styles
2

Crispin, S. M. "Ocular manifestations of hyperlipoproteinaemia." Journal of Small Animal Practice 34, no. 10 (October 1993): 500–506. http://dx.doi.org/10.1111/j.1748-5827.1993.tb03522.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jiao, S., K. Kameda, Y. Matsuzawa, and S. Tarui. "Hyperlipoproteinaemia in primary gout: hyperlipoproteinaemic phenotype and influence of alcohol intake and obesity in Japan." Annals of the Rheumatic Diseases 45, no. 4 (April 1, 1986): 308–13. http://dx.doi.org/10.1136/ard.45.4.308.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Thompson, G. N., A. J. Knight, I. H. Craig, and J. L. Bresson. "Type V hyperlipoproteinaemia in neonates." Archives of Disease in Childhood 62, no. 9 (September 1, 1987): 967–69. http://dx.doi.org/10.1136/adc.62.9.967.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Crispin, Sheila. "Ocular lipid deposition and hyperlipoproteinaemia." Progress in Retinal and Eye Research 21, no. 2 (March 2002): 169–224. http://dx.doi.org/10.1016/s1350-9462(02)00004-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Simvastatin or gemfibrozil for combined hyperlipoproteinaemia?" Inpharma Weekly &NA;, no. 1087 (May 1997): 15. http://dx.doi.org/10.2165/00128413-199710870-00034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

GILLETT, MICHAEL P. T., MOHAMMED S. LAKHANI, and GUY NATION. "Spontaneous hyperlipoproteinaemia in the Arabian dromedary." Biochemical Society Transactions 23, no. 2 (May 1, 1995): 281S. http://dx.doi.org/10.1042/bst023281s.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

&NA;. "Pravastatin has therapeutic potential in hyperlipoproteinaemia." Inpharma Weekly &NA;, no. 758 (October 1990): 17. http://dx.doi.org/10.2165/00128413-199007580-00045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gaw, Allan, and Dzifa Wosornu. "Simvastatin during warfarin therapy in hyperlipoproteinaemia." Lancet 340, no. 8825 (October 1992): 979–80. http://dx.doi.org/10.1016/0140-6736(92)92872-d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

CARELESS, D. J., M. G. COHEN, and F. LEPRE. "Mosculoskeletal Complaints in Patients with Hyperlipoproteinaemia." Rheumatology 34, no. 4 (1995): 393–94. http://dx.doi.org/10.1093/rheumatology/34.4.393.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Hyperlipoproteinaemia"

1

Schettler, Gotthard, and Andreas J. R. Habenicht. Principles and Treatment of Lipoprotein Disorders. Springer Nature, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schettler, Gotthard, and Andreas J. R. Habenicht. Principles and Treatment of Lipoprotein Disorders. Brand: Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Schettler, Gotthard, G. A. Coetzee, Andreas J. R. Habenicht, D. H. Blankenhorn, and H. B. Brewer. Principles and Treatment of Lipoprotein Disorders. Springer London, Limited, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

H, Blankenhorn David, Schettler Gotthard, and Habenicht A. 1948-, eds. Principles and treatment of lipoprotein disorders. Berlin: Springer-Verlag, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Hyperlipoproteinaemia"

1

Lorimer, A. Ross, and W. Stewart Hillis. "Atherosclerosis and Hyperlipoproteinaemia." In Treatment in Clinical Medicine, 15–27. London: Springer London, 1985. http://dx.doi.org/10.1007/978-1-4471-3120-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Acalovschi, M., A. Georeceanu, R. Badea, and D. Blendea. "Gallstone prevalence in obese women: pathogenic role of hyperlipoproteinaemia and gallbladder motility." In Recent Advances in the Epidemiology and Prevention of Gallstone Disease, 113–20. Dordrecht: Springer Netherlands, 1991. http://dx.doi.org/10.1007/978-94-011-3744-7_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Schwartzkopff, W. "Long-Term Experience of a Single Daily Dose of Bezafibrate Retard 400 in Hyperlipoproteinaemia of Types IIa, IIb, and IV." In Drugs Affecting Lipid Metabolism, 301–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71702-4_56.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Truswell, A. Stewart. "Fredrickson’s Classification of the Hyperlipoproteinaemias." In Cholesterol and Beyond, 29–31. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-8875-8_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bertolini, S., S. Valice, N. Elicio, A. Daga, S. Cuzzolaro, G. Montagna, G. Pistocchi, and R. Balestreri. "Lipoprotein Changes Induced by Bezafibrate — 200 mg t. i. d. — and by Bezafibrate in a Slow-Release Preparation — 400 mg Once a Day — in Patients with Primary Hyperlipoproteinaemia." In Drugs Affecting Lipid Metabolism, 283–90. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71702-4_53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Allhoff, Peter, Ulrich Laaser, and Joachim Heinrich. "Prevalence of Hyperlipoproteinaemias in a Random Sample of Men and in Patients with Ischaemic Heart Disease." In Kompendium der Lipid-Studien, 108–9. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-95642-3_50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

HUSKISSON, E. C., and F. DUDLEY HART. "HYPERLIPOPROTEINAEMIA (Type 2)." In Joint Disease, 63. Elsevier, 1987. http://dx.doi.org/10.1016/b978-0-7236-0571-3.50117-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

HUSKISSON, E. C., and F. DUDLEY HART. "HYPERLIPOPROTEINAEMIA (Type 4)." In Joint Disease, 64. Elsevier, 1987. http://dx.doi.org/10.1016/b978-0-7236-0571-3.50118-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"Type III hyperlipoproteinaemia." In Hyperlipidaemia 3Ed, 203–13. CRC Press, 2007. http://dx.doi.org/10.1201/b13464-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chatterjea, Dr (Brig). "Chapter-13 Hyperlipoproteinaemias (Hyperlipidaemias)." In Clinical Chemistry, 139–48. Jaypee Brothers Medical Publishers (P) Ltd., 2010. http://dx.doi.org/10.5005/jp/books/11106_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hyperlipoproteinaemia"

1

Schrör, K., P. Löbel, and E. Steinhagen-Thiessen. "SYNVINOLIN (SYN) IN TYPE Ha HYPERLIPOPROTEINAEMIA : NORMALIZED PLATELET HYPERREACTIVITY ASSOCIATED WITH AN IMPROVED RESPONSIVENESS AGAINST PGI2 AND ENHANCED PGI2 RECEPTORS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643460.

Full text
Abstract:
Patients with familial hyperlipoproteinaemia (HLP) are at high risk for the premature development of atherosclerosis. This study was designed to investigate the effect of long-term treatment (8 months) with the HMG-CoA-reductase inhibitor SYN (20-40 mg/day) on platelet reactivity and PGIo receptors in 12 HLP patients (B) as compared with 11 untreated HLP patients (A) and 11 healthy subjects (C). Treatment with SYN reduced the plasma cholesterol to 234 ± 12 mg/dl as compared to 307 ± 21 (A) and 195 ± 14 mg/dl (C), respectively. Collagen (0.6 pg/ml) induced platelet thromboxane (TXB2) formation was 50±6 ng/ml in group A and significantly reduced to 32 ± 3 (B) which was not different from the 28±3 ng/ml in group C. Similar results were obtained by measuring pTatelet ATP secretion and aggregation. SYN treatment significantly improved the reduced number of PGI2 receptors (determined according to Schillinger & Prior, 1980) and normalized the iloprost (ILO, 30 nM) induced cAMP stimulation in platelet-rich plasma while the kg remained unchanged:These data demonstrate that SYN-treatment of HLP patients at doses that reduce plasma cholesterol by about 25% results in sig-ficant improvement of platelet function. This includes both normalization of platelet hyperreactivity against proaggregatory agents as well as platelet hyporeactivity aganist PGI2. The last effect might involve an increase of the (reduced) number of PGI2 receptors in HLP type IIa.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Hyperlipoproteinaemia' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography